About the Journal

Aim and Scopes

Journal of Cancer Biomoleculars and Therapeutics (JCBT, eISSN: 3060-8856) encompasses a broad range of research areas on clinical and experimental research of cancer. The scope includes, but not limited to:

  • Molecular Oncology

Studies focusing on the molecular mechanisms that lead to cancer development and progression. This can include research on oncogenes, tumor suppressors, cancer genomics, and epigenetics.

  • Cancer Therapeutics

Research on developing new treatments for cancer, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. This may also cover drug design, development, and delivery systems.

  • Biomarkers in Cancer

Identification and validation of biomarkers for cancer diagnosis, prognosis, and treatment response.

  • Cancer Cell Biology

Investigations into cancer cell behavior, signaling pathways, cell cycle regulation, apoptosis, and tumor microenvironment.

  • Translational Research

Bridging basic science findings to clinical applications, such as the development of new diagnostic tools or therapeutic strategies based on molecular findings.

  • Personalized Medicine in Oncology

Research into individualized treatment approaches based on genetic, biomolecular, and phenotypic characteristics of both the tumor and the patient.

  • Pharmacology and Toxicology

Studies on the pharmacodynamics and pharmacokinetics of cancer drugs, including their toxicological impacts.

  • Cancer Prevention and Epidemiology

Research on cancer risk factors, preventive strategies, and the epidemiology of different types of cancer.

  • Clinical Trials

Reports on the outcomes of clinical trials for new cancer treatments, including phase I, II, III, and IV trials.

  • Innovative Therapeutic Approaches

Exploration of novel strategies in cancer treatment, such as gene therapy, nanotechnology in drug delivery, and new radiation therapy techniques.

  • Bioinformatics and Network Pharmacology

Network pharmacology integrated with bioinformatics represents a novel strategy for cancer therapeutics. This approach facilitates ingredient identification, target prediction, and treatment development, among other applications.

General Information

eISSN: 3060-8856

1st Year Published: 2024

Frequency: Quarterly

Issues Per Year: 4

Primary Language: English

Publisher Information

Publisher: ETERNO PRESS SDN. BHD., Malaysia

Edited by Pier Paolo Piccaluga in Bologna, Italy.

*(Note: This journal was published by ETERNO PRESS PTE. LTD., Singapore, for Volumes 1 and 2 (2024-2025). The transfer to the current publisher took effect on 1 January 2026.)*

Country / Region: Malaysia

Abstracted/indexed in

                                     Lens